Combined Chemotherapy and Immunotherapy Induction for Screening of Patients with Cervical Esophageal Carcinoma for Subsequent Local Treatment: A New Treatment Paradigm

Индукция комбинированной химио- и иммунотерапии для скрининга пациентов с шейным раком пищевода для последующего местного лечения: новая парадигма лечения
Liang Dai, Ya-Ya Wu, Yan Sun, Rong Yu, Wanpu Yan, Yongbo Yang, Cheng Hong, Yi-Mei Gao, Bin Zhang, Ke‐Neng Chen
2024-07-26

cervical esophageal carcinomachemoradiotherapycombined immunotherapy and chemotherapyinduction treatmentlaryngeal preservation
BACKGROUND: Definitive chemoradiotherapy is recommended as the primary treatment for cervical esophageal carcinoma (CEC). However, local control rates remain unsatisfactory for some patients. Therefore, in this study, we introduced a new treatment paradigm for individuals with CEC, customizing the choice between subsequent local treatments based on their response to induction chemotherapy and immunotherapy. PATIENTS AND METHODS: Induction treatment comprised two to four cycles of chemotherapy combined with programmed cell death protein 1 (PD-1) inhibitors. Patients achieving complete response (CR) or near CR after induction treatment underwent definitive chemoradiotherapy (dCRT), while those not achieving CR or near CR underwent surgical resection. RESULTS: Among the 40 eligible patients, 14 (35.0%) achieved a CR or near CR after induction treatment. Of the ten patients achieving a CR or near CR, one developed an esophageal fistula after dCRT (10.0%). Among the eight non-CR or non-near CR patients receiving chemoradiotherapy, six developed esophageal fistula (75.0%). Among the 26 patients who did not achieve CR or near CR after induction treatment, the 1-year cancer specific survival (CSS) rates were 93.3% [95% confidence interval (CI) 0.815-1%] for the 18 patients in the surgery group, and 71.4% (95% CI 0.447-1%) for the 8 patients in the chemoradiotherapy group (p = 0.027). The overall laryngeal preservation rate was 85.0% (34/40), with a functional laryngeal preservation rate of 77.5% (31/40). CONCLUSION: The approach consisting of combined immunotherapy and chemotherapy successfully identified patients who were responding well to induction treatment and who were sensitive to radiotherapy, for chemoradiotherapy; thus, improving laryngeal preservation rates. In addition, it also identified patients with poor responses to induction treatment and radiotherapy, for timely surgery; hence, reducing radiotherapy complications and enhancing survival.
1
Combined induction of chemotherapy and immunotherapy successfully identified cervical esophageal carcinoma patients who responded well and were sensitive to subsequent radiotherapy.
2
Selecting surgery for poor responders reduced radiotherapy-related complications and enhanced survival.
3
The induction approach identified patients with poor responses to induction and radiotherapy, allowing timely surgery for those patients.
4
Using this combined induction to select patients for chemoradiotherapy improved laryngeal preservation rates.

Patients with cervical esophageal carcinoma undergoing combined chemotherapy and immunotherapy induction

Use of combined chemotherapy and immunotherapy induction to screen and stratify patients for subsequent local treatments (chemoradiotherapy to preserve the larynx or timely surgery), based on response and radiotherapy sensitivity, and its impact on treatment selection, laryngeal preservation, complications, and survival

Publication Details
Publication Date
2024-07-26
Journal
Publisher
ISSN
Cited by
4
Access Type
Author Information
Authors
Liang Dai
Ya-Ya Wu
Yan Sun
Rong Yu
Wanpu Yan
Yongbo Yang
Cheng Hong
Yi-Mei Gao
Bin Zhang
Ke‐Neng Chen
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%